Impel NeuroPharma appoints Stewart Parker to the Board of Directors

– USA, WA – Impel NeuroPharma is pleased to announce that H. Stewart Parker, a prominent leader in Seattle’s Biotechnology community, has joined Impel’s Board of Directors.

Most recently, Parker was the CEO of the Seattle-based Infection Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines, and treatments for neglected diseases. Parker started her career in biotech as the first employee of Immunex, growing with the company to become Vice President of Corporate Development. In 1992, Parker founded the Immunex offshoot Targeted Genetics, a Seattle biotech company focused on developing gene-based treatments for acquired and inherited disease. Parker served as President and CEO of Targeted Genetics for seventeen years until her retirement in 2008.

Parker has since been active on a number of boards, including the University of Washington’s College of Arts & Science, C3 Jian, OncoGenex Pharmaceuticals, and Sangamo BioSciences. Parker is a graduate of the MBA program at the University of Washington’s Foster School of Business with an undergraduate degree in Slavic languages and literature.

“Stewart is an acknowledged leader in the biotechnology community, building multiple organizations and working with teams to scale their operations,” notes Mike Hite, Impel’s CEO. “For us, Stewart is bringing an exceptional amount of experience and strategic perspective that will be beneficial as Impel establishes its future course and the next stage of growth.”

About Impel NeuroPharma

Impel NeuroPharma was founded with a mission to enable drugs to bypass the blood brain barrier. Co-founders John Hoekman, Ph.D., and Michael Hite, MBA, began their work together in 2008 at the University of Washington and developed a technical concept into an enabling, marketable technology. Their innovations have materialized into a rapidly growing med-tech company that has attracted seasoned professionals committed to developing a robust technology platform for nose-to-brain drug delivery.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.